- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Test efficacy of umifenovir alone, not with favipiravir for COVID cure: CDSCO panel to Macleods Pharma
New Delhi: Mumbai-based Macleods Pharma recently asked permission to test the influenza drug, Umifenovir Hydrochloride along with Favipiravir, as a potential Covid-19 treatment. However, the Subject Expert Committee functional under the Central Drugs Standard Control Organisation (CDSCO) declined the proposal, while directing it to test the effectiveness of the Russian drug alone, and not in combination with Favipiravir.
The proposed formulation, Umifenovir is primarily used for the treatment of influenza, mainly in Russia and China. It is a broad‐spectrum antiviral agent that could "effectively inhibit the fusion of a virus with host cells", claims a study in the National Center for Biotechnology Information (NCBI). It further added that previous research has elucidated that umifenovir is an efficient inhibitor of SARS‐CoV‐2 in vitro.
Sold under brand name Arbidol, the possible efficacy of umifenovir in COVID‐19 has been a prime focus of more and more researchers off late.
Macleods too showed keen interest in assessing Umifenovir Hydrochloride capsule 50/100/200mg in combination with another promising drug - Favipiravir.
Accordingly, it moved an application for approval of Umifenovir HCl in COVID19. However, the firm presented its proposal for a clinical trial of Umifenovir and Favipiravir along with standard supportive care verses favipiravir along with standard supportive care in hospitalized subjects with moderate COVID-19 Infection.
The application was examined in a meeting held last month regarding the COVID-19 related proposal under the accelerated approval process at the CDSCO headquarter.
It was noted that the drugmaker had filed a proposal to check the efficacy of the "single drug", umifenovir hydrochloride, but sought permission to test it along with favipiravir.
After detailed deliberation, the subject expert committee (SEC), which advises the Drug Controller General of India (DCGI), asked the company to revise the proposal to check for the efficacy of umifenovir alone.
"The committee recommended that the firm should submit an appropriate protocol for evaluation of the safety & efficacy of Umifenovir Hydrochloride Capsules as their application is for approval of Umifenovir Hydrochloride single drug," the minutes of the meeting read.
Also Read: Unichem, Macleods Pharma Recall Drugs From US Market
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751